A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
← catalyst calendarNCT03773965 · readout ≤ 1,806 d
Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
190estimated
Sites
78
Countries
Argentina, Australia, Austria +17
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-04-05 | actual | When the study began enrolling |
| Primary completion | Jul 2031 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jul 2031 | estimated | The whole study's end, after follow-up |
| First posted | 2018-12-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Juvenile Idiopathic Arthritis
Intervention
- Drug: Baricitinib — also filed as LY3009104
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants with One or More Serious Adverse Event(s) (SAEs)
measured Baseline through Week 264
Number of Participants with Permanent Investigational Product Discontinuations
measured Baseline through Week 264
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed